| Trial ID: | L0470 |
| Source ID: | NCT03912532
|
| Associated Drug: |
NGM282
|
| Title: |
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of NGM282 Administered for 24 Weeks for the Treatment of Histologically Confirmed Nonalcoholic Steatohepatitis (
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Biological: NGM282;Other: Placebo
|
| Outcome Measures: |
Proportion of participants achieving a histologic treatment effect (histologic response) as determined by the NASH CRN criteria after 24 weeks of NGM282 or matched placebo.;Evaluate safety and tolerability of NGM282 in participants with NASH as a function of dose level after up to 24 weeks of treatment with NGM282.nan
|
| Sponsor/Collaborators: |
NGM Biopharmaceuticals, Inc
|
| Gender: |
All
|
| Age: |
18 Years75 Years
|
| Phases: |
Phase 2
|
| Enrollment: |
171
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
| Start Date: |
09/04/2019
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
17 January 2022
|
| Locations: |
United States;Puerto Rico;United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03912532
|
